CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19).
Treatments for neuroendocrine carcinoma of unknown primary
Neuroendocrine carcinoma of unknown primary (CUP) is usually treated with chemotherapy or targeted therapy. Your healthcare team may suggest chemotherapy or targeted therapy based on your needs and work with you to develop a treatment plan.
Combination chemotherapy is the main treatment for neuroendocrine CUP. The drugs given will depend on if the cancer is poorly differentiated or well differentiated.
Poorly differentiated neuroendocrine CUP and small cell CUP are usually treated with either:
- cisplatin (Platinol AQ) and etoposide (Vepesid, VP-16)
- carboplatin (Paraplatin, Paraplatin AQ) and etoposide
Well differentiated neuroendocrine CUP may be treated with streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU).
Targeted therapy may be offered to people with neuroendocrine carcinoma of unknown primary. The drugs used are:
- sunitinib (Sutent)
- everolimus (Afinitor)
If you can’t have or don’t want cancer treatment
You may want to consider a type of care to make you feel better rather than treat the cancer itself. This may be because the cancer treatments don’t work anymore, they’re not likely to improve your condition or they may cause side effects that are hard to cope with. There may also be other reasons why you can’t have or don’t want cancer treatment.
Talk to your healthcare team. They can help you choose care and treatment for advanced cancer.
You may be asked if you want to join a clinical trial for cancer of unknown primary. Find out more about clinical trials.
Great progress has been made
Some cancers, such as thyroid and testicular, have survival rates of over 90%. Other cancers, such as pancreatic, brain and esophageal, continue to have very low survival rates.